Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease.

Autor: Ariz M; Ciberonc and Biomedical Engineering Program, CIMA University of Navarra, Pamplona, Spain.; Department of Electrical, Electronic and Communications Engineering, Public University of Navarre, Pamplona, Spain., Martínez M; Neuroimaging Laboratory, University of Navarra, School of Medicine, Pamplona, Spain., Alvarez I; Movement Disorders Unit, Neurology, University Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain., Fernández-Seara MA; Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Castellanos G; Department of Physiological Sciences, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia., Pastor P; Unit of Neurodegenerative Diseases, Department of Neurology, University Hospital Germans Trias i Pujol, and Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain., Pastor MA; Neuroimaging Laboratory, University of Navarra, School of Medicine, Pamplona, Spain.; Movement Disorders Unit, Neurology, University of Navarra, Pamplona, Spain., Ortiz de Solórzano C; Ciberonc and Biomedical Engineering Program, CIMA University of Navarra, Pamplona, Spain.; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Jazyk: angličtina
Zdroj: Journal of magnetic resonance imaging : JMRI [J Magn Reson Imaging] 2024 Aug; Vol. 60 (2), pp. 534-547. Date of Electronic Publication: 2023 Nov 02.
DOI: 10.1002/jmri.29073
Abstrakt: Background: There is a lack of automated tools for the segmentation and quantification of neuromelanin (NM) and iron in the nigrosome-1 (N1). Existing tools evaluate the N1 sign, i.e., the presence or absence of the "swallow-tail" in iron-sensitive MRI, or globally analyze the MRI signal in an area containing the N1, without providing a volumetric delineation.
Purpose: Present an automated method to segment the N1 and quantify differences in N1's NM and iron content between Parkinson's disease (PD) patients and healthy controls (HCs). Study whether N1 degeneration is clinically related to PD and could be used as a biomarker of the disease.
Study Type: Prospective.
Subjects: Seventy-one PD (65.3 ± 10.3 years old, 34 female/37 male); 30 HC (62.7 ± 7.8 years old, 17 female/13 male).
Field Strength/sequence: 3 T Anatomical T1-weighted MPRAGE, NM-MRI T1-weighted gradient with magnetization transfer, susceptibility-weighted imaging (SWI).
Assessment: N1 was automatically segmented in SWI images using a multi-image atlas, populated with healthy N1 structures manually annotated by a neurologist. Relative NM and iron content were quantified and their diagnostic performance assessed and compared with the substantia nigra pars compacta (SNc). The association between image parameters and clinically relevant variables was studied.
Statistical Tests: Nonparametric tests were used (Mann-Whitney's U, chi-square, and Friedman tests) at P = 0.05.
Results: N1's relative NM content decreased and relative iron content increased in PD patients compared with HCs (NM-CR HC  = 22.55 ± 1.49; NM-CR PD  = 19.79 ± 1.92; NM-nVol HC  = 2.69 × 10 -5  ± 1.02 × 10 -5 ; NM-nVol PD  = 1.18 × 10 -5  ± 0.96 × 10 -5 ; Iron-CR HC  = 10.51 ± 2.64; Iron-CR PD  = 19.35 ± 7.88; Iron-nVol HC  = 0.72 × 10 -5  ± 0.81 × 10 -5 ; Iron-nVol PD  = 2.82 × 10 -5  ± 2.04 × 10 -5 ). Binary logistic regression analyses combining N1 and SNc image parameters yielded a top AUC = 0.955. Significant correlation was found between most N1 parameters and both disease duration (ρ NM-CR  = -0.31; ρ iron-CR  = 0.43; ρ iron-nVol  = 0.46) and the motor status (ρ NM-nVol  = -0.27; ρ iron-CR  = 0.33; ρ iron-nVol  = 0.28), suggesting NM reduction along with iron accumulation in N1 as the disease progresses.
Data Conclusion: This method provides a fully automatic N1 segmentation, and the analyses performed reveal that N1 relative NM and iron quantification improves diagnostic performance and suggest a relative NM reduction along with a relative iron accumulation in N1 as the disease progresses.
Evidence Level: 1 TECHNICAL EFFICACY: Stage 1.
(© 2023 Fundación para la Investigación Médica Aplicada. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.)
Databáze: MEDLINE
Externí odkaz: